Global Idiopathic Pulmonary Fibrosis (IPF) Market Report 2024-2034: IPF Industry to Observe Robust Expansion with Emerging Therapies and Increasing Prevalence of Cough-Related IPF [Yahoo! ...
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Yahoo! Finance
This report focuses on the global Idiopathic Pulmonary Fibrosis (IPF) market and its expanding trajectory regarding the specific symptom of cough. The report presents an all-encompassing view of the IPF market dynamics, including the diagnosis, severity of symptoms, current therapeutic strategies, and future growth prospects. Highlighting the significant impact of cough in IPF on patients' quality of life, the report brings to attention the projected growth of this niche sector in seven major markets (7MM)—the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. According to the research, the market for Cough in IPF is forecasted to experience consistent growth through 2034, fueled by an anticipated rise in diagnosed prevalent cases and the introduction of emerging therapies that could transform current treatment paradigms. Current treatment approaches largely consist of off-label therapies, with corticosteroids and neuromodulators being the
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024 [Yahoo! Finance]Yahoo! Finance
- Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024PR Newswire
- Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
- Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference [Yahoo! Finance]Yahoo! Finance
- Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International ConferencePR Newswire
TRVI
Earnings
- 3/20/24 - Beat
TRVI
Sec Filings
- 4/29/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- TRVI's page on the SEC website